pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
737
stories
Jul 29, 26
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
Jul 29, 26
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
Jul 28, 26
STAT+: FDA staff reiterate concerns about Replimune skin cancer treatment
stat
Jul 28, 26
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
Jul 28, 26
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
stat
Jul 27, 26
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
Jul 27, 26
Apnimed aspires for up to $160M IPO as sleep apnea pill launch nears
fiercebiotech
Jul 27, 26
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
Jul 24, 26
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
stat
Jul 24, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Jul 24, 26
STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
stat
Jul 24, 26
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
Jul 24, 26
Roche cans one Carmot obesity asset as another shows best-in-class potential
biospace
Jul 24, 26
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
stat
Jul 23, 26
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
Jul 23, 26
STAT+: European regulators take steps to bolster clinical trial transparency
stat
Jul 23, 26
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 23, 26
FDA panel confronting peptide controversy
stat
Jul 23, 26
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
Jul 23, 26
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
Jul 23, 26
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
Jul 23, 26
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
biospace
Jul 23, 26
Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add on
biospace
Jul 23, 26
Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins
endpoints
Jul 23, 26
STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
stat
Jul 23, 26
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts near
endpoints
Jul 23, 26
Opinion: New billing codes likely to raise maternity care costs
stat
Jul 23, 26
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
Jul 23, 26
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 22, 26
STAT+: Pharma tries to tamp down broad China restrictions
stat
← prev
page 16 of 25
next →